GlassScriptPhysician profile
Gregory M Swor
NPI 1447439245
$6,573.26
in general payments reported to CMS, 2019-2025
59 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $409 · 2021: $1,163 · 2022: $1,783 · 2023: $601 · 2024: $333 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $2,120.23 | 2019-2022 | |
| Abbvie INC. | $531.09 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Cytyc Surgical Products, LLC | $450.00 | 2021 | |
| Bolder Surgical LLC | $315.50 | 2019-2021 | |
| Myovant Sciences INC. | $271.17 | 2021-2022 | |
| Hologic Sales and Service, LLC | $241.86 | 2019-2024 | Thinprep 2000 Processor, Aptima, Affirm Prone Biopsy System |
| Astellas Pharma US INC | $240.52 | 2019-2025 | Veozah |
| Therapeuticsmd, INC. | $212.63 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $198.04 | 2023-2025 | Myfembree |
| Baxter Healthcare | $186.04 | 2024-2025 | Seprafilm, Adept, Tisseel |
| Pfizer INC. | $178.21 | 2020-2025 | |
| Caldera Medical, INC | $151.62 | 2023 | Desara |
| Exeltis, USA INC. | $112.99 | 2021-2023 | Slynd |
| Covidien LP | $106.01 | 2019-2020 | |
| Scynexis, INC. | $83.89 | 2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $82.81 | 2021-2022 | |
| Organon LLC | $64.69 | 2021-2025 | Nexplanon |
| Coopersurgical, INC. | $58.25 | 2020-2022 | |
| Smith+Nephew, INC. | $57.88 | 2019-2025 | Pico, Renasys Touch |
| Amag Pharmaceuticals, INC. | $56.17 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.35 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $55.17 | 2021-2023 | |
| Axonics, INC. | $52.79 | 2021-2023 | Axonics |
| Avion Pharmaceuticals | $51.93 | 2019-2023 | Balcoltra |
| Channel Medsystems, INC. | $49.78 | 2023-2024 | |
| Daiichi Sankyo INC. | $47.54 | 2021-2022 | |
| Cepheid | $43.45 | 2025 | |
| Gynesonics, INC. | $42.02 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Lupin INC. | $41.27 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $37.07 | 2021-2023 | Gardasil 9 |
| Laborie Medical Technologies Corp. | $36.78 | 2022-2023 | |
| Millicent US INC | $36.73 | 2019-2020 | |
| Allergan, INC. | $36.71 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $32.47 | 2020-2022 | |
| Exact Sciences Corporation | $22.96 | 2023 | Cologuard Collection Kit |
| Ethicon US, LLC | $22.87 | 2022 | |
| Biogen, INC. | $22.56 | 2025 | Zurzuvae |
| Meditrina | $17.54 | 2025 | |
| Minerva Surgical, INC | $17.22 | 2019 | |
| Duchesnay USA Incorporated | $16.78 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.01 | 2019 | |
| Roche Diagnostics Corporation | $15.42 | 2019 | |
| Coloplast Corp | $15.42 | 2022 | |
| Aspira Women'S Health INC | $13.91 | 2020 | |
| Medtronic, INC. | $13.89 | 2025 | Ligasure |
| Mylan Pharmaceuticals INC. | $13.44 | 2020 | |
| Karl Storz Endoscopy-America | $13.39 | 2024 | |
| Medtronic USA, INC. | $13.19 | 2019 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Swor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.